Solid Tumor Recruiting Phase 1 Trials for Oxaliplatin (DB00526)
Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0030180 (Solid Tumor) | Recruiting | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Treatment | |
| NCT06576037 | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Treatment | |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Treatment | |
| NCT05382559 | A Study of ASP3082 in Adults With Advanced Solid Tumors | Treatment | |
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Treatment | |
| NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors | Treatment | |
| NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | Treatment | |
| NCT05067283 | A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Treatment | |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Treatment | |
| NCT06719362 | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies | Treatment | |
| NCT05719558 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Treatment | |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Treatment | |
| NCT06179160 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Treatment | |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | Treatment | |
| NCT07477743 | A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors | Treatment |
|
| NCT06350006 | SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor | Treatment |